235 related articles for article (PubMed ID: 18484590)
1. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.
Al Otaibi M; Ross P; Fahmy N; Jeyaganth S; Trottier H; Sircar K; Bégin LR; Souhami L; Kassouf W; Aprikian A; Tanguay S
Cancer; 2008 Jul; 113(2):286-92. PubMed ID: 18484590
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
6. An analysis of men with clinically localized prostate cancer who deferred definitive therapy.
Patel MI; DeConcini DT; Lopez-Corona E; Ohori M; Wheeler T; Scardino PT
J Urol; 2004 Apr; 171(4):1520-4. PubMed ID: 15017211
[TBL] [Abstract][Full Text] [Related]
7. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
Abouassaly R; Lane BR; Jones JS
Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
9. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
[TBL] [Abstract][Full Text] [Related]
10. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.
Gallo F; Chiono L; Gastaldi E; Venturino E; Giberti C
Urology; 2008 Sep; 72(3):628-32. PubMed ID: 18279918
[TBL] [Abstract][Full Text] [Related]
13. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
14. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.
Boccon-Gibod LM; de Longchamps NB; Toublanc M; Boccon-Gibod LA; Ravery V
J Urol; 2006 Sep; 176(3):961-3; discussion 963-4. PubMed ID: 16890668
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
16. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
[TBL] [Abstract][Full Text] [Related]
17. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
18. Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer.
Puppo P; Introini C; Calvi P; Naselli A
Eur Urol; 2006 May; 49(5):873-8. PubMed ID: 16439052
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
20. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer.
Choo R; Do V; Sugar L; Klotz L; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
Can J Urol; 2004 Feb; 11(1):2118-24. PubMed ID: 15003150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]